Hobbach Anastasia Janina, Feld Jannik, Sindermann Jürgen Reinhard, Reinecke Holger
Department of Cardiology I, Coronary, Peripheral Vascular Disease and Heart Failure, University Hospital Münster, Albert-Schweizer Campus 1, 48149, Münster, Germany.
Institute of Biostatistics and Clinical Research, University of Münster, Schmeddingstraße 56, 48149, Münster, Germany.
Clin Res Cardiol. 2025 May 26. doi: 10.1007/s00392-025-02679-4.
Chronic left ventricular heart failure (CLHF) represents a significant public health challenge globally, marked by high morbidity and mortality. CLHF is a leading cause of hospitalization, placing considerable strain on healthcare systems. This study aims to analyze in-hospital outcomes for CLHF patients in Germany over nine years (2014-2022), examining trends in morbidity, mortality, healthcare costs, and complications.
Data were sourced from the Federal Statistical Office (DESTATIS), covering 2,616,462 inpatient CLHF cases (ICD-10-GM I50.11-I50.14) in Germany from 2014 to 2022. CLHF hospitalizations increased from 288,019 in 2014 to 311,782 in 2019, then declined in 2020 but started again to rise from 2021 to 2022. The proportion of patients with advanced CLHF (NYHA stage IV) decreased slightly from 54.09% in 2014 to 50.36% in 2020 (p < 0.0001). Notable comorbidity trends included rising rates of atrial fibrillation and chronic kidney disease. Complications such as cardiogenic shock and acute kidney injury increased over time (both p < 0.0001). Despite a decrease in mortality rates from 2014 to 2019 (p < 0.0001), in-hospital mortality rose to 8.84% in 2022 (p < 0.0001). Median revenue volume and hospitalization duration showed a pre-pandemic increase but declined in 2020.
The study highlights a complex interplay of factors affecting CLHF management in Germany, as a representative example for a high-income country. While advancements in treatment have improved some outcomes, the COVID-19 pandemic significantly impacted hospitalization trends and in-hospital mortality. The findings underscore the need for ongoing improvements in CLHF management and resilient healthcare strategies to address future challenges.
慢性左心室心力衰竭(CLHF)是全球重大的公共卫生挑战,具有高发病率和高死亡率。CLHF是住院的主要原因,给医疗系统带来了巨大压力。本研究旨在分析德国九年间(2014 - 2022年)CLHF患者的院内结局,研究发病率、死亡率、医疗成本和并发症的趋势。
数据来源于联邦统计局(DESTATIS),涵盖2014年至2022年德国2,616,462例住院CLHF病例(国际疾病分类第十版 - 德国修正版I50.11 - I50.14)。CLHF住院病例从2014年的288,019例增加到2019年的311,782例,2020年下降,但从2021年到2022年又开始上升。晚期CLHF(纽约心脏协会IV级)患者的比例从2014年的54.09%略有下降至2020年的50.36%(p < 0.0001)。显著的合并症趋势包括心房颤动和慢性肾脏病发病率上升。心源性休克和急性肾损伤等并发症随时间增加(两者p < 0.0001)。尽管2014年至2019年死亡率下降(p < 0.0001),但2022年院内死亡率升至8.84%(p < 0.0001)。中位数收入额和住院时长在疫情前有所增加,但2020年下降。
该研究突出了影响德国CLHF管理的多种因素之间复杂的相互作用,德国作为高收入国家的代表案例。虽然治疗进展改善了一些结局,但新冠疫情显著影响了住院趋势和院内死亡率。研究结果强调了持续改善CLHF管理和制定有弹性的医疗策略以应对未来挑战的必要性。